US laboratories get regulatory break under new CLIA (Clinical Laboratory Improvement Amendment) rules
This article was originally published in Clinica
Executive Summary
Many of the laboratories that market FDA-approved products face new more stringent quality control requirements under a final rule published last week by the Centers for Medicare and Medicaid Services (CMS).